About us

DeepkinetiX provides a cost-effective, faster, more precise, and ethically superior alternative to traditional animal-based methods. By leveraging digital twin technology, DeepkinetiX accurately predicts effective dosages and potential clinical side effects of drug candidates during the early development stages. This ensures streamlined processes and more reliable outcomes, accelerating the delivery of lifesaving therapies to patients in need.

DeepkinetiX provides a cost-effective, faster, more precise, and ethically superior alternative to traditional animal-based methods. By leveraging digital twin technology, DeepkinetiX accurately predicts effective dosages and potential clinical side effects of drug candidates during the early development stages. This ensures streamlined processes and more reliable outcomes, accelerating the delivery of lifesaving therapies to patients in need.

Our team

Ali Ghayoor,

PhD

Co-founder & CEO

Hamed Kohan, PharmD, PhD

Co-founder & CSO

Amir Aref,

PhD

Co-founder & CDO